Compare TLF & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLF | APM |
|---|---|---|
| Founded | 1980 | 2010 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.0M | 18.9M |
| IPO Year | N/A | 2018 |
| Metric | TLF | APM |
|---|---|---|
| Price | $2.73 | $1.29 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 18.2K | ★ 108.9K |
| Earning Date | 11-10-2025 | 12-19-2025 |
| Dividend Yield | ★ 55.35% | N/A |
| EPS Growth | ★ 308.92 | N/A |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $74,550,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.36 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.56 | $0.65 |
| 52 Week High | $5.48 | $7.49 |
| Indicator | TLF | APM |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | 40.40 |
| Support Level | $2.66 | $1.22 |
| Resistance Level | $2.77 | $1.38 |
| Average True Range (ATR) | 0.14 | 0.13 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 27.66 | 15.69 |
Tandy Leather Factory Inc is a specialty retailers of leather and leathercraft-related items. Its primary line of business is the sale of leather, leather crafts, and related supplies. Its broad line of leather and related products includes leather, leatherworking tools, leather dyes and finishes, and do-it-yourself kits. Its products include Leather, tools, Hardware, Supplies, Kits, Books and Patterns, and Gift cards. The company sells its products primarily through company-owned stores and through orders generated from its global websites, and through direct account representatives in its commercial division. Geographically the company operates within the United States, Canada and others and generates the highest revenue from the United States.
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.